2025 Q3 -tulosraportti
42 päivää sitten36 min
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 26.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 1.12.2025 | |
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2025 Q1 -tulosraportti | 25.4.2025 | |
| 2024 Q4 -tulosraportti | 27.2.2025 | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Datan lähde: FactSet, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·12 t sitten · MuokattuAn estimate of the probabilities in the model before the JPM conference: (conditional probabilities) STEP 3a (75–85 %) Tests whether uTREAT can even deliver measurable radiation dose in humans (1-2 patients) → This is the least ambitious test: is the signal found, and is safety acceptable? → The risk here is primarily technical and translational (test already performed in animals - can it be demonstrated in humans?) Status: much of it has already been reduced via uTRACE, preclinical data and first-in-human dosing without safety issues. Investor intuition: If the technology works in principle, a first signal is expected in at least one patient. STEP 3b (45–60 %) Tests whether the signal can be repeated in 2-3 patients with a reasonably similar profile. → Here, biological variation is introduced, especially in GBM, which is extremely heterogeneous. → The requirement is not identical data – but that the variation is understandable and within an acceptable range. Investor intuition: The market moves from “case” to “pattern”. The risk increases because real patients are never identical. STEP 3c (25–35 %) Tests whether data are robust enough to support a scalable platform (5-6 patients) → Now it's not just about whether it works – but whether it works stably enough for Big Pharma to make irreversible strategic decisions. → Small inconsistencies, outliers or unclear dosimetry ratio are of great importance here. Investor intuition: STEP 3c is not clinically more difficult – but strategically harder. This is where the requirements shift from “is it possible?” to “do we dare to own it?” I think they are already enrolling the 2nd patient in the Phase 1 study, as there are approx. 50 patients in Dk. per year who could potentially benefit from participating in the trial. So within a short time (1-2 weeks) we can have data for Step 3a. If Step 3a shows that they can reach 60 Gy, it is a completely different robust case. It will be a game-changer on many parameters. Strategic significance (very important): A 60 Gy signal in FPD means that: • Big Pharma no longer discusses physics/delivery • Focus shifts to: o variability o patient selection o dose optimization o indication expansion 👉 Strategic dialogues can accelerate immediately, even before patients 2–3 are finished. If uTREAT already in the first patient delivers ~60 Gy to tumor without safety issues, the central technical risk in the case is practically addressed. It shifts focus from “can it work?” to “how stably can it be repeated?” - and significantly increases the probability of strategic interest. 60 Gy in FPD: STEP 3a (+90 %): Not just passed – passed with a safety margin. STEP 3b (60-70%): The probability increases because physics/delivery has already been proven. STEP 3c (35-40%): Still the hardest barrier – but now a platform discussion, not an existence discussion. --------------------- Wonder what they have in their briefcase for the dialogues with Big Pharma at the JPM conference...? Have they already achieved 60 Gy in FPD and are they talking about it under an NDA? Yes, it could very well turn out to be a very exciting week ahead of us..😉
·20 t sittenCurasight's cancer platform takes center stage during J.P. Morgan week Curasight strategically uses the J.P. Morgan Healthcare Conference to position itself as a serious player in radiopharmaceuticals and theranostics. With both a diagnostic product in phase 2 (uTRACE®) and a therapeutic product that has just entered clinical phase 1 (uTREAT®), the company can present a rare combination of clinical momentum and platform thinking to an investor audience that specifically demands differentiated oncological solutions. The integrated “see-and-treat” strategy strengthens the scientific and commercial rationale, as uTRACE® reduces treatment risk by identifying the patients who can truly benefit from uTREAT®. At the same time, the partnership with Curium provides important external validation, a clear commercialization path, and non-dilutive financing, which mitigates a significant part of the early biotech risk. Conversely, Curasight remains in a capital- and regulatory-heavy phase, particularly on the therapy side, where clinical efficacy has not yet been documented. Value creation is therefore highly dependent on positive clinical data and continued access to capital. Overall, however, the company appears well-positioned to leverage the structural growth in the radiopharmaceutical market and use J.P. Morgan week as a lever for partnerships and long-term value. https://briefglance.com/articles/curasights-cancer-platform-takes-center-stage-at-jp-morgan-week?fbclid=IwZnRzaAPQYs5leHRuA2FlbQIxMQBzcnRjBmFwcF9pZAo2NjI4NTY4Mzc5AAEeV6tL7w00t1NP5XrUt3nJroDDUF81xMWotzrC-SUI57u3nG6ks0C5QnhJLOo_aem_crNkmCoG0sKbBljKWiTfhA
·1 päivä sittenExciting week ahead! Have found two articles concerning Curasight's participation in the upcoming conference: https://briefglance.com/articles/curasights-cancer-platform-takes-center-stage-at-jp-morgan-week (Published 6 days ago) Excerpt from the article: Riding the Radiopharmaceutical Wave Curasight is developing its platform at a time of explosive growth in the radiopharmaceutical market. Driven by the success of approved therapies and a deeper understanding of targeted radiation, the sector is attracting massive investment and M&A activity. Market research reports consistently project robust growth, with some estimates suggesting the market could swell from around $10 billion in 2024 to over $30 billion by the early 2030s, posting a compound annual growth rate well into the double digits. This boom is fueled by a broader shift in oncology toward precision medicine. Radiopharmaceuticals like uTRACE® and uTREAT® are at the forefront of this trend, offering the potential for highly effective, personalized treatments with more manageable side-effect profiles than traditional chemotherapy or external beam radiation. The ability to target cancer at a molecular level is transforming treatment paradigms for diseases like prostate cancer and neuroendocrine tumors, and companies are racing to apply the concept to other malignancies. By focusing on the well-documented uPAR target, which is implicated in numerous cancer types, Curasight's platform has broad potential applicability. Its progress in brain and prostate cancer serves as an important proof of concept, positioning the company as a significant player in this dynamic and rapidly expanding field of medicine. The discussions at J.P. Morgan will therefore not only be about Curasight's individual progress but also about how it fits into one of the most exciting growth stories in modern healthcare.
22 t sitten · Muokattu22 t sitten · MuokattuBriefglance: Curasight arrives with powerful momentum, armed with fresh clinical progress updates. The discussions are expected to center on two key programs: the recent initiation of a Phase 1 trial of its therapeutic agent, uTREAT®, in patients with aggressive brain cancer, and the steady advancement of its diagnostic tool, uTRACE®, in a Phase 2 trial for prostate cancer. For a company at this stage, the J.P. Morgan conference week is more than a networking event; it's a critical venue to validate its science, strategy, and investment potential on a global stage. 🔥
·2 päivää sittenHas anyone tried asking Curasight why we haven't received the preliminary read-out promised in q4-2025? Could there be more patients? We are already well over a week into 2026 now
·2 päivää sittenIt took longer than "expected" before first dose. There are only 50 patients per year at Rigshospitalet and not all are suitable or wish to participate in a trial. For example, they may only have one tumor, not be undergoing treatment, not have other forms of cancer etc etc. Some may also be too weak and others too young. This is also a safety and dose study. They have already announced that there were no problems with the first patient. So that is more or less the result we could hope for with this trial where there are only 6 patients in total. Do not expect results in this trial that uTREAT performs miracles and the cancer tumor disappears. Maybe the dose will be adjusted up for the next patients and if the first patient gets another round. Then it might be possible to start seeing an effect with a new scan.
·2 päivää sittenIt will be exciting to see if, during next week, some new interested foreign/American buyers of Curasight shares suddenly emerge. One thing is certain....they will NOT be allowed to buy mine...!! 😅
·2 päivää sittenSerious question: wouldn't they make a deal with a fixed share price at Curasight that bypasses the publicly traded shares?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
42 päivää sitten36 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·12 t sitten · MuokattuAn estimate of the probabilities in the model before the JPM conference: (conditional probabilities) STEP 3a (75–85 %) Tests whether uTREAT can even deliver measurable radiation dose in humans (1-2 patients) → This is the least ambitious test: is the signal found, and is safety acceptable? → The risk here is primarily technical and translational (test already performed in animals - can it be demonstrated in humans?) Status: much of it has already been reduced via uTRACE, preclinical data and first-in-human dosing without safety issues. Investor intuition: If the technology works in principle, a first signal is expected in at least one patient. STEP 3b (45–60 %) Tests whether the signal can be repeated in 2-3 patients with a reasonably similar profile. → Here, biological variation is introduced, especially in GBM, which is extremely heterogeneous. → The requirement is not identical data – but that the variation is understandable and within an acceptable range. Investor intuition: The market moves from “case” to “pattern”. The risk increases because real patients are never identical. STEP 3c (25–35 %) Tests whether data are robust enough to support a scalable platform (5-6 patients) → Now it's not just about whether it works – but whether it works stably enough for Big Pharma to make irreversible strategic decisions. → Small inconsistencies, outliers or unclear dosimetry ratio are of great importance here. Investor intuition: STEP 3c is not clinically more difficult – but strategically harder. This is where the requirements shift from “is it possible?” to “do we dare to own it?” I think they are already enrolling the 2nd patient in the Phase 1 study, as there are approx. 50 patients in Dk. per year who could potentially benefit from participating in the trial. So within a short time (1-2 weeks) we can have data for Step 3a. If Step 3a shows that they can reach 60 Gy, it is a completely different robust case. It will be a game-changer on many parameters. Strategic significance (very important): A 60 Gy signal in FPD means that: • Big Pharma no longer discusses physics/delivery • Focus shifts to: o variability o patient selection o dose optimization o indication expansion 👉 Strategic dialogues can accelerate immediately, even before patients 2–3 are finished. If uTREAT already in the first patient delivers ~60 Gy to tumor without safety issues, the central technical risk in the case is practically addressed. It shifts focus from “can it work?” to “how stably can it be repeated?” - and significantly increases the probability of strategic interest. 60 Gy in FPD: STEP 3a (+90 %): Not just passed – passed with a safety margin. STEP 3b (60-70%): The probability increases because physics/delivery has already been proven. STEP 3c (35-40%): Still the hardest barrier – but now a platform discussion, not an existence discussion. --------------------- Wonder what they have in their briefcase for the dialogues with Big Pharma at the JPM conference...? Have they already achieved 60 Gy in FPD and are they talking about it under an NDA? Yes, it could very well turn out to be a very exciting week ahead of us..😉
- ·20 t sittenCurasight's cancer platform takes center stage during J.P. Morgan week Curasight strategically uses the J.P. Morgan Healthcare Conference to position itself as a serious player in radiopharmaceuticals and theranostics. With both a diagnostic product in phase 2 (uTRACE®) and a therapeutic product that has just entered clinical phase 1 (uTREAT®), the company can present a rare combination of clinical momentum and platform thinking to an investor audience that specifically demands differentiated oncological solutions. The integrated “see-and-treat” strategy strengthens the scientific and commercial rationale, as uTRACE® reduces treatment risk by identifying the patients who can truly benefit from uTREAT®. At the same time, the partnership with Curium provides important external validation, a clear commercialization path, and non-dilutive financing, which mitigates a significant part of the early biotech risk. Conversely, Curasight remains in a capital- and regulatory-heavy phase, particularly on the therapy side, where clinical efficacy has not yet been documented. Value creation is therefore highly dependent on positive clinical data and continued access to capital. Overall, however, the company appears well-positioned to leverage the structural growth in the radiopharmaceutical market and use J.P. Morgan week as a lever for partnerships and long-term value. https://briefglance.com/articles/curasights-cancer-platform-takes-center-stage-at-jp-morgan-week?fbclid=IwZnRzaAPQYs5leHRuA2FlbQIxMQBzcnRjBmFwcF9pZAo2NjI4NTY4Mzc5AAEeV6tL7w00t1NP5XrUt3nJroDDUF81xMWotzrC-SUI57u3nG6ks0C5QnhJLOo_aem_crNkmCoG0sKbBljKWiTfhA
- ·1 päivä sittenExciting week ahead! Have found two articles concerning Curasight's participation in the upcoming conference: https://briefglance.com/articles/curasights-cancer-platform-takes-center-stage-at-jp-morgan-week (Published 6 days ago) Excerpt from the article: Riding the Radiopharmaceutical Wave Curasight is developing its platform at a time of explosive growth in the radiopharmaceutical market. Driven by the success of approved therapies and a deeper understanding of targeted radiation, the sector is attracting massive investment and M&A activity. Market research reports consistently project robust growth, with some estimates suggesting the market could swell from around $10 billion in 2024 to over $30 billion by the early 2030s, posting a compound annual growth rate well into the double digits. This boom is fueled by a broader shift in oncology toward precision medicine. Radiopharmaceuticals like uTRACE® and uTREAT® are at the forefront of this trend, offering the potential for highly effective, personalized treatments with more manageable side-effect profiles than traditional chemotherapy or external beam radiation. The ability to target cancer at a molecular level is transforming treatment paradigms for diseases like prostate cancer and neuroendocrine tumors, and companies are racing to apply the concept to other malignancies. By focusing on the well-documented uPAR target, which is implicated in numerous cancer types, Curasight's platform has broad potential applicability. Its progress in brain and prostate cancer serves as an important proof of concept, positioning the company as a significant player in this dynamic and rapidly expanding field of medicine. The discussions at J.P. Morgan will therefore not only be about Curasight's individual progress but also about how it fits into one of the most exciting growth stories in modern healthcare.22 t sitten · Muokattu22 t sitten · MuokattuBriefglance: Curasight arrives with powerful momentum, armed with fresh clinical progress updates. The discussions are expected to center on two key programs: the recent initiation of a Phase 1 trial of its therapeutic agent, uTREAT®, in patients with aggressive brain cancer, and the steady advancement of its diagnostic tool, uTRACE®, in a Phase 2 trial for prostate cancer. For a company at this stage, the J.P. Morgan conference week is more than a networking event; it's a critical venue to validate its science, strategy, and investment potential on a global stage. 🔥
- ·2 päivää sittenHas anyone tried asking Curasight why we haven't received the preliminary read-out promised in q4-2025? Could there be more patients? We are already well over a week into 2026 now·2 päivää sittenIt took longer than "expected" before first dose. There are only 50 patients per year at Rigshospitalet and not all are suitable or wish to participate in a trial. For example, they may only have one tumor, not be undergoing treatment, not have other forms of cancer etc etc. Some may also be too weak and others too young. This is also a safety and dose study. They have already announced that there were no problems with the first patient. So that is more or less the result we could hope for with this trial where there are only 6 patients in total. Do not expect results in this trial that uTREAT performs miracles and the cancer tumor disappears. Maybe the dose will be adjusted up for the next patients and if the first patient gets another round. Then it might be possible to start seeing an effect with a new scan.
- ·2 päivää sittenIt will be exciting to see if, during next week, some new interested foreign/American buyers of Curasight shares suddenly emerge. One thing is certain....they will NOT be allowed to buy mine...!! 😅·2 päivää sittenSerious question: wouldn't they make a deal with a fixed share price at Curasight that bypasses the publicly traded shares?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 26.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 1.12.2025 | |
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2025 Q1 -tulosraportti | 25.4.2025 | |
| 2024 Q4 -tulosraportti | 27.2.2025 | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Datan lähde: FactSet, Quartr
2025 Q3 -tulosraportti
42 päivää sitten36 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 26.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 1.12.2025 | |
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2025 Q1 -tulosraportti | 25.4.2025 | |
| 2024 Q4 -tulosraportti | 27.2.2025 | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Datan lähde: FactSet, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·12 t sitten · MuokattuAn estimate of the probabilities in the model before the JPM conference: (conditional probabilities) STEP 3a (75–85 %) Tests whether uTREAT can even deliver measurable radiation dose in humans (1-2 patients) → This is the least ambitious test: is the signal found, and is safety acceptable? → The risk here is primarily technical and translational (test already performed in animals - can it be demonstrated in humans?) Status: much of it has already been reduced via uTRACE, preclinical data and first-in-human dosing without safety issues. Investor intuition: If the technology works in principle, a first signal is expected in at least one patient. STEP 3b (45–60 %) Tests whether the signal can be repeated in 2-3 patients with a reasonably similar profile. → Here, biological variation is introduced, especially in GBM, which is extremely heterogeneous. → The requirement is not identical data – but that the variation is understandable and within an acceptable range. Investor intuition: The market moves from “case” to “pattern”. The risk increases because real patients are never identical. STEP 3c (25–35 %) Tests whether data are robust enough to support a scalable platform (5-6 patients) → Now it's not just about whether it works – but whether it works stably enough for Big Pharma to make irreversible strategic decisions. → Small inconsistencies, outliers or unclear dosimetry ratio are of great importance here. Investor intuition: STEP 3c is not clinically more difficult – but strategically harder. This is where the requirements shift from “is it possible?” to “do we dare to own it?” I think they are already enrolling the 2nd patient in the Phase 1 study, as there are approx. 50 patients in Dk. per year who could potentially benefit from participating in the trial. So within a short time (1-2 weeks) we can have data for Step 3a. If Step 3a shows that they can reach 60 Gy, it is a completely different robust case. It will be a game-changer on many parameters. Strategic significance (very important): A 60 Gy signal in FPD means that: • Big Pharma no longer discusses physics/delivery • Focus shifts to: o variability o patient selection o dose optimization o indication expansion 👉 Strategic dialogues can accelerate immediately, even before patients 2–3 are finished. If uTREAT already in the first patient delivers ~60 Gy to tumor without safety issues, the central technical risk in the case is practically addressed. It shifts focus from “can it work?” to “how stably can it be repeated?” - and significantly increases the probability of strategic interest. 60 Gy in FPD: STEP 3a (+90 %): Not just passed – passed with a safety margin. STEP 3b (60-70%): The probability increases because physics/delivery has already been proven. STEP 3c (35-40%): Still the hardest barrier – but now a platform discussion, not an existence discussion. --------------------- Wonder what they have in their briefcase for the dialogues with Big Pharma at the JPM conference...? Have they already achieved 60 Gy in FPD and are they talking about it under an NDA? Yes, it could very well turn out to be a very exciting week ahead of us..😉
- ·20 t sittenCurasight's cancer platform takes center stage during J.P. Morgan week Curasight strategically uses the J.P. Morgan Healthcare Conference to position itself as a serious player in radiopharmaceuticals and theranostics. With both a diagnostic product in phase 2 (uTRACE®) and a therapeutic product that has just entered clinical phase 1 (uTREAT®), the company can present a rare combination of clinical momentum and platform thinking to an investor audience that specifically demands differentiated oncological solutions. The integrated “see-and-treat” strategy strengthens the scientific and commercial rationale, as uTRACE® reduces treatment risk by identifying the patients who can truly benefit from uTREAT®. At the same time, the partnership with Curium provides important external validation, a clear commercialization path, and non-dilutive financing, which mitigates a significant part of the early biotech risk. Conversely, Curasight remains in a capital- and regulatory-heavy phase, particularly on the therapy side, where clinical efficacy has not yet been documented. Value creation is therefore highly dependent on positive clinical data and continued access to capital. Overall, however, the company appears well-positioned to leverage the structural growth in the radiopharmaceutical market and use J.P. Morgan week as a lever for partnerships and long-term value. https://briefglance.com/articles/curasights-cancer-platform-takes-center-stage-at-jp-morgan-week?fbclid=IwZnRzaAPQYs5leHRuA2FlbQIxMQBzcnRjBmFwcF9pZAo2NjI4NTY4Mzc5AAEeV6tL7w00t1NP5XrUt3nJroDDUF81xMWotzrC-SUI57u3nG6ks0C5QnhJLOo_aem_crNkmCoG0sKbBljKWiTfhA
- ·1 päivä sittenExciting week ahead! Have found two articles concerning Curasight's participation in the upcoming conference: https://briefglance.com/articles/curasights-cancer-platform-takes-center-stage-at-jp-morgan-week (Published 6 days ago) Excerpt from the article: Riding the Radiopharmaceutical Wave Curasight is developing its platform at a time of explosive growth in the radiopharmaceutical market. Driven by the success of approved therapies and a deeper understanding of targeted radiation, the sector is attracting massive investment and M&A activity. Market research reports consistently project robust growth, with some estimates suggesting the market could swell from around $10 billion in 2024 to over $30 billion by the early 2030s, posting a compound annual growth rate well into the double digits. This boom is fueled by a broader shift in oncology toward precision medicine. Radiopharmaceuticals like uTRACE® and uTREAT® are at the forefront of this trend, offering the potential for highly effective, personalized treatments with more manageable side-effect profiles than traditional chemotherapy or external beam radiation. The ability to target cancer at a molecular level is transforming treatment paradigms for diseases like prostate cancer and neuroendocrine tumors, and companies are racing to apply the concept to other malignancies. By focusing on the well-documented uPAR target, which is implicated in numerous cancer types, Curasight's platform has broad potential applicability. Its progress in brain and prostate cancer serves as an important proof of concept, positioning the company as a significant player in this dynamic and rapidly expanding field of medicine. The discussions at J.P. Morgan will therefore not only be about Curasight's individual progress but also about how it fits into one of the most exciting growth stories in modern healthcare.22 t sitten · Muokattu22 t sitten · MuokattuBriefglance: Curasight arrives with powerful momentum, armed with fresh clinical progress updates. The discussions are expected to center on two key programs: the recent initiation of a Phase 1 trial of its therapeutic agent, uTREAT®, in patients with aggressive brain cancer, and the steady advancement of its diagnostic tool, uTRACE®, in a Phase 2 trial for prostate cancer. For a company at this stage, the J.P. Morgan conference week is more than a networking event; it's a critical venue to validate its science, strategy, and investment potential on a global stage. 🔥
- ·2 päivää sittenHas anyone tried asking Curasight why we haven't received the preliminary read-out promised in q4-2025? Could there be more patients? We are already well over a week into 2026 now·2 päivää sittenIt took longer than "expected" before first dose. There are only 50 patients per year at Rigshospitalet and not all are suitable or wish to participate in a trial. For example, they may only have one tumor, not be undergoing treatment, not have other forms of cancer etc etc. Some may also be too weak and others too young. This is also a safety and dose study. They have already announced that there were no problems with the first patient. So that is more or less the result we could hope for with this trial where there are only 6 patients in total. Do not expect results in this trial that uTREAT performs miracles and the cancer tumor disappears. Maybe the dose will be adjusted up for the next patients and if the first patient gets another round. Then it might be possible to start seeing an effect with a new scan.
- ·2 päivää sittenIt will be exciting to see if, during next week, some new interested foreign/American buyers of Curasight shares suddenly emerge. One thing is certain....they will NOT be allowed to buy mine...!! 😅·2 päivää sittenSerious question: wouldn't they make a deal with a fixed share price at Curasight that bypasses the publicly traded shares?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt